Latest Content

Most US patients eligible for hepatitis B virus (HBV) treatment remain untreated, raising risks of liver disease and complications.

Baricitinib demonstrated significant reductions in disease activity in postmenopausal women with frontal fibrosing alopecia over 12 weeks.

The FDA expanded approvals for key medications, enhancing treatment options for atopic dermatitis, inflammatory bowel disease, type 2 diabetes, and more.

The FDA has approved pembrolizumab and enfortumab vedotin for muscle-invasive bladder cancer (MIBC), offering new hope for patients ineligible for cisplatin.

Individuals told their absolute risk of HIV had higher interest in pre-exposure prophylaxis (PrEP) compared with those told relative risk.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Scientists restored the CCNA2 gene in adult human heart cells, enabling them to divide and form new functional cardiomyocytes—advancing heart repair therapies.

Remibrutinib demonstrated rapid and sustained symptom relief for chronic spontaneous urticaria in a pooled analysis of REMIX-1 and REMIX-2.

Survivors of SJS/TEN face severe long-term physical and psychological effects, with major gaps in post-discharge care, support, and physician guidance.